Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

Open access
Black, Madison, Barsoum, Ivraym B., Truesdell, Peter, Cotechini, Tiziana, Macdonald-Goodfellow, Shannyn K., Petroff, Margaret, Siemens, D. Robert, Koti, Madhuri, Craig, Andrew W.B., Graham, Charles H.·2016·Oncotarget

Abstract

// Madison Black 1 , Ivraym B. Barsoum 1,2 , Peter Truesdell 1,4 , Tiziana Cotechini 1 , Shannyn K. Macdonald-Goodfellow 1 , Margaret Petroff 3 , D. Robert Siemens 1,2 , Madhuri Koti 1,4 , Andrew W.B. Craig 1,4 and Charles H. Graham 1,2,4 1 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada 2 Department of Urology, Queen’s University, Kingston, Ontario, Canada 3 Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, Michigan, USA 4 Cancer Biology and Genetics, Queen’s Cancer Research Institute, Kingston, Ontario, Canada Correspondence to: Charles H. Graham, email: // Keywords : PD-1, PD-L1, chemoresistance, immune escape, metastasis Received : December 04, 2015 Accepted : January 25, 2016 Published : February 07, 2016 Abstract The ability of tumor cells to avoid immune destruction (immune escape) as well as their acquired resistance to anti-cancer drugs constitute important barriers to the successful management of cancer. Interaction between the Programmed Death Ligand 1 (PD-L1) on the surface of tumor cells with the Programmed Death-1 (PD-1) receptor on cytotoxic T lymphocytes leads to inactivation of these immune effectors and, consequently, immune escape. Here we show that the PD-1/PD-L1 axis also leads to tumor cell resistance to conventional chemotherapeutic agents. Using a panel of PD-L1-expressing human and mouse breast and prostate cancer cell lines, we found that incubation of breast and prostate cancer cells in the presence of purified recombinant PD-1 resulted in resistance to doxorubicin and docetaxel as determined using clonogenic survival assays. Co-culture with PD-1-expressing Jurkat T cells also promoted chemoresistance and this was prevented by antibody blockade of either PD-L1 or PD-1 or by silencing of the PD-L1 gene. Moreover, inhibition of the PD-1/PD-L1 axis using anti-PD-1 antibody enhanced doxorubicin chemotherapy to inhibit metastasis in a syngeneic mammary orthotopic mouse model of metastatic breast cancer. To further investigate the mechanism of tumor cell survival advantage upon PD-L1 ligation, we show that exposure to rPD-1 promoted ERK and mTOR growth and survival pathways leading to increased cell proliferation. Overall, the findings of this study indicate that combinations of chemotherapy and immune checkpoint blockade may limit chemoresistance and progression to metastatic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7235

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 182

Metadata

Authors
Black, M., Barsoum, I. B., Truesdell, P., Cotechini, T., Macdonald-Goodfellow, S. K., Petroff, M., Siemens, D. R., Koti, M., Craig, A. W. B., & Graham, C. H.
Venue
Oncotarget
Published
2016-02-07
Volume
7
Issue
9
Pages
10557-10567
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2270816365
Cited by
182
References
4
FWCI
10.20
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. https://app.cochat.ai/papers/10.18632/oncotarget.7235
The paper
Black, M., Barsoum, I. B., Truesdell, P., Cotechini, T., Macdonald-Goodfellow, S. K., Petroff, M., Siemens, D. R., Koti, M., Craig, A. W. B., & Graham, C. H. (2016). Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget. https://doi.org/10.18632/oncotarget.7235

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.